argenx SE (STU:1AE)
€ 553.6 6 (1.1%) Market Cap: 33.43 Bil Enterprise Value: 30.56 Bil PE Ratio: 0 PB Ratio: 8.44 GF Score: 82/100

argenx SE To Discuss the Adhere Results Transcript

Jul 17, 2023 / 12:30PM GMT
Release Date Price: €438.2 (+31.95%)
Operator

Good morning, everyone, and welcome to the argenx ADHERE trial top line results conference call. (Operator Instructions)

I would now like to introduce Beth DelGiacco, Vice President of Investor Relations and Communications at argenx. Beth, please proceed.

Beth DelGiacco
argenx SE - VP and Global Head of Corporate Communications & IR

Thank you, and good morning to everyone on the call. Earlier today, we issued the press release summarizing over positive top line and ADHERE trail results. The press release and the presentation for today's webcast can be found on our website. On the call today are Tim Van Hauwermeiren our Chief Executive Officer; Luc Truyen our Chief Medical Officer; and Karen Massey, our Chief Operating Officer. Karl Gubitz, our Chief Financial Officer, will also be available for the Q&A session following prepared remarks.

Before we begin, I'd like to remind you on Slide 2 that forward-looking statements may be presented during this call. These may include statements about our future expectations, clinical development,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot